Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events

  • Keith B. Hoffman | AdverseEvents Inc., Healdsburg, CA, United States.
  • Brian M. Overstreet AdverseEvents Inc., Healdsburg, CA, United States.
  • P. Murali Doraiswamy Departments of Psychiatry and Medicine, Duke University Medical Center, Durham, NC, United States.


Rigorous clinical trials under the watchful eye of regulators remain the cornerstone of drug safety. However, the emergence of serious and life-threatening Adverse Events (AEs) across best-selling drug classes [sometimes many years after winning Food and Drug Administration (FDA) approval] underscores the limitations of current clinical trial processes and reinforces the need for careful post-approval pharmacovigilance. The FDA’s sizeable repository of patient case reports linking AEs to approved drugs is the Adverse Event Reporting System (FAERS). We believe that open and user-friendly access to the millions of case reports in FAERS would help advance the field of post-marketing pharmacovigilance. However, FAERS data are virtually inaccessible to most physicians, pharmacists, and consumers. Accordingly, we have recently launched a big data platform ( that, unlike previous efforts, provides on-demand, user-friendly, and high-impact access to FAERS data. Bringing the power of big data to regular users, such as clinicians, pharmacists, and patients, is the logical next step in the transformation of health care to a model of shared decision making between consumers and the system.


Download data is not yet available.


PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.



Original Articles
patient safety, adverse events, side effects, drug safety, post-marketing, FDA, FAERS, AERS
  • Abstract views: 3276

  • PDF: 533
How to Cite
Hoffman, K., Overstreet, B., & Doraiswamy, P. M. (2013). Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events. Drugs and Therapy Studies, 3(1), e4.